AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma

Introduction: AVEN, an apoptosis and caspase activation inhibitor, has been associated with adverse clinical outcomes and poor prognosis in Acute myeloid leukemia (AML). Targeting AVEN in AML improves apoptosis sensitivity and chemotherapy efficacy, making it a promising therapeutic target. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Dengxia, Yang, Moses, Lee, Hye Jung, Lee, Jeong Hee, Kim, Hong Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613694/
https://www.ncbi.nlm.nih.gov/pubmed/37908231
http://dx.doi.org/10.3389/fmolb.2023.1265359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613694/
https://www.ncbi.nlm.nih.gov/pubmed/37908231
http://dx.doi.org/10.3389/fmolb.2023.1265359

Ejemplares similares